Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNC210 in hospitalized elderly patients with agitation
NCT03548194Phase 2Completed
- Sponsor
- Neuphoria Therapeutics Inc.
- Start
- May 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of soclenicant in agitation, sponsored by Neuphoria Therapeutics Inc.. Started May 2018; status: completed.
02
Drugs
soclenicant
03
Conditions
agitation
Beyond the preview
Go deeper on NCT03548194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03548194.